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Abstract
Background: Currently available pharmacological and non-pharmacological treatments have shown only modest
effects in slowing the progression of dementia. Our objective was to assess the impact of a long-term non-
pharmacological group intervention on cognitive function in dementia patients and on their ability to carry out
activities of daily living compared to a control group receiving the usual care.
Methods: A randomized, controlled, single-blind longitudinal trial was conducted with 98 patients (follow-up: n =
61) with primary degenerative dementia in five nursing homes in Bavaria, Germany. The highly standardized
intervention consisted of motor stimulation, practice in activities of daily living, and cognitive stimulation (acronym
MAKS). It was conducted in groups of ten patients led by two therapists for 2 hours, 6 days a week for 12 months.
Control patients received treatment as usual. Cognitive function was assessed using the cognitive subscale of the
Alzheimer’s Disease Assessment Scale (ADAS-Cog), and the ability to carry out activities of daily living using the
Erlangen Test of Activities of Daily Living (E-ADL test) at baseline and after 12 months.
Results: Of the 553 individuals screened, 119 (21.5%) were eligible and 98 (17.7%) were ultimately included in the study.
At 12 months, the results of the per protocol analysis (n = 61) showed that cognitive function and the ability to carry out
activities of daily living had remained stable in the intervention group but had decreased in the control patients (ADAS-
Cog: adjusted mean difference: -7.7, 95% CI -14.0 to -1.4, P =0 . 0 1 8 ,C o h e n ’s d = 0.45; E-ADL test: adjusted mean
difference: 3.6, 95% CI 0.7 to 6.4, P = 0.015, Cohen’sd=0 . 5 0 ) .T h ee f f e c ts i z e sf o rt h ei n t e r v e n t i o nw e r eg r e a t e ri nt h e
subgroup of patients (n = 50) with mild to moderate disease (ADAS-Cog: Cohen’s d = 0.67; E-ADL test: Cohen’sd=0 . 6 9 ) .
Conclusions: A highly standardized, non-pharmacological, multicomponent group intervention conducted in a
nursing-home setting was able to postpone a decline in cognitive function in dementia patients and in their ability
to carry out activities of daily living for at least 12 months.
Trial Registration: http://www.isrctn.com Identifier: ISRCTN87391496
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Background
In the absence of effective treatment for the causes of
degenerative dementias, the primary objective of pharma-
cological and non-pharmacological therapy remains to
slow disease progression. Although acetylcholinesterase
inhibitors have been shown to have a positive impact on
cognitive function in patients with Alzheimer’sd i s e a s ea n d
on their ability to carry out activities of daily living (ADL)
[1-3], these agents also have a variety of dose-dependent
adverse effects [2-4]. These and the limited efficacy [3,5]
of currently available anti-dementia drugs have led to
increased scientific interest in non-pharmacological
interventions.
A wide array of such interventions has been developed
over the past two decades [6-9], ranging from cognitive
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approaches [12] and sensory stimulation [13,14]. Cogni-
tive training, especially, has been evaluated in a number
of randomized controlled trials (RCTs). In a recent ran-
domized trial with small sample size, for example [15],
there was a significant improvement in the ADAS-Cog
after a six-month-cognitive intervention. Yet this effect
could only be seen in the subgroup of patients with
Mild Cognitive Impairment. In another recent RCT [16]
Spector et al. also found a significant effect of a 14-ses-
sion cognitive group treatment on the total ADAS-Cog
(P = 0.01). Most of the different approaches mentioned
above, however, have involved unimodal therapy and
have demonstrated limited effectiveness [15,17], if they
have been evaluated at all. It seems reasonable to
assume that because people who live independently are
confronted in their everyday lives with multiple chal-
lenges and stimuli, interventions aimed at slowing dis-
ease progression in dementia patients should also
consist of multiple components [4]. This has been
underscored by a recent systematic review, which
demonstrated the efficacy of multicomponent interven-
tions for dementia patients in achieving a range of out-
comes [18]. In their review, the authors found a Grade
B recommendation for multicomponent interventions
for dementia patients for improvement in cognition and
ADL. Of all 179 studies included, the authors detected
only 13 high quality trials regarding different interven-
tions (one for cognitive training, none for abilities of
daily living). One multicomponent intervention combin-
ing cognitive and motor elements [19] had significant
effects on cognitive abilities after 12 months but no sig-
nificant effect on patients’ abilities to carry out ADL. In
another RCT combining reality orientation training with
reminiscence therapy [20], the authors found a signifi-
cant effect on cognition immediately after intervention.
We thus designed a therapy known by the acronym
MAKS, with each letter standing for a component of the
intervention: M for motor stimulation, A for ADL, K for
cognitive stimulation (the German word being kognitiv),
and S for a short introductory phase with what we
called a spiritual element (for example, discussing topics
such as happiness or singing a song, usually a hymn).
The cognitive component aimed to have a direct effect,
and the motor exercises an indirect effect [7,21-23], on
higher cognitive functions [24-26]. Practicing ADL was
intended to slow the loss of independence typically seen
in dementia patients [27,28].
Proving a causal relationship between a non-pharma-
cological intervention and a therapeutic effect requires a
rigorous methodological approach, such as that
demanded of pharmacological studies, including a ran-
domized, controlled design, validated outcome measures,
blinded testing, control for other medication and non-
drug influences, and recording of serious adverse events
[29]. The present investigation attempts to meet these
standards. We hypothesized that patients who partici-
pated in the MAKS intervention would show better cog-
nitive function and less impairment in ADL than
control patients after 12 months. The results for the
other measures used in the study-direct care time, neu-
ropsychiatric symptoms, and functional independence-
will be reported elsewhere.
Methods
Study design
We conducted a randomized, controlled, single-blind
longitudinal study examining the efficacy of a multicom-
ponent, non-pharmacological group therapy known as
MAKS in dementia patients in five German nursing
homes. Therapy was conducted six days a week and
lasted for twelve months, beginning in December 2008
and ending in December 2009 (Figure 1).
We determined the size of the sample based on the
interim results of a pilot study [30], which used the
same outcome measures as in the present analysis and
showed an effect size of 0.67 (Cohen’sd )f o rA D Li na n
experimental-control group comparison after six
months. Power analysis (one-tailed testing) revealed that
a sample size of 29 in each group (that is, 58 patients in
total) would be required, with the significance level (a)
and test power (1-b) set at 0.05 and 0.80, respectively.
Between October and December 2008, we screened all
residents (N = 553) in five nursing homes in Mittelfran-
ken, a district within the German state of Bavaria. The
nursing homes were of a similar size (between 100 and
134 residents) and were all operated by the same organi-
zation, the Diakonie Neuendettelsau. Therefore, they
were also similar in terms of corporate philosophy and
the range of non-MAKS activities offered by the homes.
We applied the following inclusion criteria: presence of
primary degenerative dementia according to ICD-10
(F00, F03, or G30) and as confirmed by the attending
physician; fewer than 24 points on the Mini-Mental
State Examination (MMSE) [31]; and written informed
consent by patients and, where necessary, their legal
guardians prior to baseline. The form sheet, all legal
conditions and the study design were examined by the
Ethics Committee of the Medical Faculty of the Univer-
sity of Erlangen. Approval was granted on 10 July 2008
(Registration Number 3232). Exclusion criteria were as
follows: vascular (F01) or secondary (F02) dementia
according to ICD-10; the presence of other neurologi-
cal/psychiatric diseases that could explain patients’
decline in cognitive function (such as addiction, major
depression, or schizophrenia); very high nursing care
needs (that is, care level 3, which is the highest level on
the three-level scale currently used to determine
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Page 2 of 11eligibility for nursing care benefits in Germany); deaf-
ness; or blindness. Taking medication of any type did
not affect inclusion or exclusion in our study (see Table
1 for medication taken).
Of the 119 patients determined to be eligible (that is,
between 18 and 27 patients in each of the 5 nursing
homes), 98 were ultimately randomized to either the
MAKS or the control group one week prior to the
553 nursing home residents 
assessed for eligibility (i.e. 
all residents of 5 nursing 
homes independent of 
diagnosis) 
434 excluded  
      9 blind 
      5 deaf 
      8 other reasons 
    20 physical reasons (for 
example, dialysis)  
    39 unwilling to participate 
    47 no degenerative dementia 
according to attending 
physician  
  48 unable to communicate 
  128 MMSE score >24 
  130 care level 3/bedridden 
31 analysed PP  
41 analysed ITT  
0 excluded from analysis  
19 drop-outs 
Reasons: 
3 died  
4 refused  
5 care level 3/bedridden 
7 absent more than 3 weeks 
 
Additionally 6 persons died after 
dropout and before follow up 
therefore 9 persons are lost for ITT-
analysis 
50 allocated to intervention 
group, which received MAKS 
therapy 
 
16 drop-out 
Reasons: 
6 died 
1 refused 
6  care level 3/bedridden 
3 moved away 
 
Additionally 2 persons died after 
dropout and before follow up therefore 
8 persons are lost for ITT-analysis 
 
 
48 allocated to control group, 
which received  
treatment as usual.    
30 analysed PP  
38 analysed ITT  
2 excluded from analysis  
Reason: late information provided 
by physician about former alcohol 
abuse and probable Korsakoff’s 
syndrome 
Baseline 
12-month 
analysis 
 
12-month 
follow-up 
Enrollment 
98 randomised 
(max. 20 persons 
per nursing home) 
Figure 1 CONSORT flowchart of study design.
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Page 3 of 11commencement of therapy. We computer generated a
randomization list for each home, assigning 10 patients
to each treatment group and 10 patients to each control
group. In one nursing home, only 18 eligible patients
could be randomized (10 to the treatment group and 8
to the control group). Control patients received treat-
ment as usual instead of MAKS therapy.
T h es t u d yd i dn o ti n t e r f e r ei na n yw a yw i t hp a t i e n t s ’
existing pharmacological treatment, nursing care, or
with their participation in the regular activities offered
by the nursing home outside of the MAKS study. Inde-
pendent evaluators, who were blinded to treatment allo-
cation and were not part of the nursing home staff,
recorded the outcome measures at baseline (before com-
mencement of therapy) and after 12 months (in
December 2009/January 2010, after completion of ther-
apy). Data were anonymized and submitted to the cen-
tral study site.
Quality assurance measures
The evaluators took part in two training sessions with
actor patients prior to the start of data recording and in
a third training session six months later. The nursing
home staff, which included therapists, aides, and one
study coordinator per nursing home, also received train-
ing in data recording. To ensure the quality of the data
recorded at the five participating nursing homes, the
study design was explained in detail to the coordinators.
Assistants from the central study site conducted random
on-location checks of the coordinators’ documentation.
Table 1 Characteristics of patients (randomized at baseline, n = 96)
Characteristics Intervention group
(n = 50)
Control group
(n = 46)
Total
(n = 96)
Test for group
differences
Test for nursing home
differences
f
c
2 t
e P Value c
2 P Value
Age, mean (SD) 84.5 (4.5) 85.7 (5.7) 85.1 (5.1) 1.19 0.24 4.91 0.30
Women, no. (%) 44 (88.0) 36 (78.3) 80 (83.3) 1.64 0.20 5.84 0.21
Educational attainment, no. (%) 3.85 0.43 14.08 0.01
No school completed 5 (10.9) 9 (20.9) 14 (15.7)
Elementary/secondary school 39 (84.7) 30 (69.8) 69 (77.5)
University preparatory 2 (4.3) 3 (7.0) 5 (5.6)
University 0 (0.0) 1 (2.3) 1 (1.1)
Marital status, no. (%) 5.25 0.15 2.62 0.62
Married 4 (8.0) 9 (19.6) 13 (13.5)
Widowed 40 (80.0) 34 (73.9) 74 (77.1)
Divorced 0 (0) 1 (2.2) 1 (1)
Single 6 (12.0) 2 (4.3) 8 (8.3)
MMSE mean (SD) 15.4 (5.4) 13.8 (5.4) 14.6 (5.4) -1.45 0.15 1.68 0.79
NOSGER subscale mood, mean (SD) 10.6 (3.1) 9.9 (3.0) 10.3 (3.1) -1.07 0.29 5.03 0.29
Care level
a, no. (%) 4.63 0.10 4.56 0.34
None 7 (14.0) 2 (4.3) 9 (9.4)
1 27 (54.0) 21 (45.7) 48 (50.0)
2 16 (32.0) 23 (50.0) 39 (40.6)
3 0 (0) 0 (0) 0 (0)
Charlson comorbidity index
b, mean (SD) 1.1 (1.6) 1.1 (1.6) 1.1 (1.4) -0.31 0.76 7.35 0.12
Use of anti-dementia med.
c, no. (%) 9 (18.0) 4 (8.7) 13 (13.5) 1.80 0.18 5.48 0.24
Medication score
d, mean (SD) -1.4 (1.7) -1.5 (1.7) -1.5 (1.7) -0.11 0.91 0.93 0.92
ADAS-Cog, mean (SD) 33.5 (13.1) 38.0 (14.4) 35.6 (13.8) 1.60 0.11 12.11 0.02
E-ADL test, mean (SD) 25.9 (5.4) 23.7 (5.9) 24.7 (5.7) -1.62 0.10 9.69 0.05
Abbreviations: MMSE, Mini-Mental State Examination; NOSGER, Nurses’ Observation Scale for Geriatric Patients; ADAS-Cog, Alzheimer’s Disease Assessment Scale,
subscale cognition; E-ADL test, Erlangen Test of Activities of Daily Living.
aThe care level describes the extent to which nursing care is needed: none (no needs), 1 (moderate needs), 2 (high needs), and 3 (very high needs). This scale is
used in Germany to establish eligibility for nursing care benefits. Put simply, individuals who need regular assistance with activities of everyday living and
household chores for a daily average of at least 1.5 hours are assigned to level 1, those who need at least 3 hours of assistance to level 2, and those who need 5
or more hours of assistance to level 3. The classification is conducted by an organization formed by the long-term care insurance funds, which are statutory
entities that administer the system of long-term care insurance in Germany.
bCharlson comorbidity index: Effect of comorbidities (that is, in addition to dementia)
on mortality rate. A condition is assigned a score according to the mortality risk associated with it. One-year mortality increases from 12% (index = 0) to 85%
(index ≥ 5) as the score increases.
cAnti-dementia medication during the intervention period: intervention group: 3× acetylcholinesterase (AChE) inhibitors, 7×
memantine, 1× both; control group: 2× AChE inhibitors, 2× memantine.
dMedication score: mean value of all medications taken by the patient. It was calculated
using all prescribed medications at baseline, including anti-dementia drugs. To do so, two experts from the University of Erlangen’s Department of Clinical
Pharmacology rated all medications in terms of their sedating or stimulating effect or side effect using a 5-step scale: -2 (very sedating), -1 (sedating), 0 (neither
sedating nor stimulating), +1 (stimulating), +2 (very stimulating).
edf = 94.
fwith Kruskal-Wallis or Pearson c
2 with df = 5.
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nursing home staff recorded and reported any serious
adverse events that occurred during the study period.
These were defined as falls resulting in injury, serious
injury of any other type requiring a physician’s attention,
or death. A Data Monitoring and Safety Board, which
consisted of four external experts from different profes-
sions, oversaw the implementation of the study and
monitored for serious adverse events every three
months.
Implementation of treatment
MAKS therapy was conducted in each nursing home by
two therapists and one aide from Monday through
Saturday from 9:30 am to 11:30 am for 12 months. The
therapists were registered nurses for the elderly. Each
therapy group consisted of 10 dementia patients. Thera-
pists and aides received a standardized handbook from
the central study site describing in detail the steps to be
taken on each day of therapy. This guaranteed that on
any given day the same tasks would be performed at
each nursing home. The handbook was developed speci-
fically for the present study by a study scientist
(psychologist).
To ensure that the handbook was used in a standar-
dized manner in all five nursing homes, we provided
therapists and aides with two complete days of training
prior to the commencement of therapy and one day of
follow-up training after four months. A team from the
central study site monitored compliance with the hand-
book by conducting three on-location checks per home.
As an additional quality assurance measure, therapists
were required to record any deviations from the hand-
book. Compliance with the handbook was 97.5% in the
five nursing homes.
Attendance of participants was stringently monitored
by therapists and study coordinators in the homes. Par-
ticipants who completed the whole intervention period
only missed 3% of the intervention days on average. The
minimum attendance for not being excluded from the
study was 50%.
Treatment conditions
MAKS is a multicomponent group therapy consisting of
tasks organized into three categories-motor stimulation
(M), ADL (A), and cognition (K)-preceded by a short
introduction consisting of what we called a spiritual ele-
ment (S).
Each daily session began with this introduction, which
lasted approximately 10 minutes and was designed to
help the dementia patients feel part of the group. It con-
sisted of a round of greetings followed by a group song
( u s u a l l yah y m n )o rad i s c u s s i o na b o u tam e a n i n g f u l
topic, such as happiness. This was followed by about 30
minutes of motor exercises, such as bowling, croquet, or
balancing a tennis ball on a frisbee and passing it to
one’s neighbor. After a 10 minute break, the patients
spent approximately 30 minutes completing a variety of
cognitive tasks, ranging from paper and pencil exercises,
such as solving word jumbles or matching symbols into
pairs, to picture puzzles projected digitally onto a large
screen to be solved by the group. MAKS was designed
to promote activity that takes place at an individual’s
performance limit. Therefore, therapists matched all
participants into three homogenous groups according to
the individual performance levels (operationalized with
MMSE-score) and assigned the cognitive tasks from one
of three difficulty levels to the appropriate group. This
was followed by about 40 minutes during which patients
carried out ADL (such as preparing a snack), engaged in
creative tasks (such as working with wood, paper, or
other natural materials), or did simple gardening work
(for further examples see Appendix 2 and 3 in Addi-
tional file 1).
The control group received the usual care offered in
each nursing home and were free to participate in any
of the regular, non-MAKS activities offered at the home,
such as memory training, physical exercises to reduce
the risk of falling, cooking groups, or occupational ther-
apy (for an overview of all non-MAKS activities see
Appendix 4 in Additional file 1). Patients in the control
group participated in an average of two of these non-
MAKS activities per week. Patients in the MAKS group
were also free to take part in these activities in addition
to MAKS and did so once a week on the average.
Outcome measures
The two outcome measures included in the present ana-
lysis-cognitive function and the ability to carry out
ADL-were recorded by evaluators (students of Psychol-
ogy in their last year) who had received training, did not
belong to the nursing home staff, and were blinded to
treatment allocation. During the examination, which
took place in each patient’s room, only the patient, the
evaluator, and, if necessary, a nurse were present. The
evaluator used the cognitive subscale of the Alzheimer’s
Disease Assessment Scale (ADAS-Cog) [32] to measure
function. The scoring range for ADAS-Cog is from 0 to
70, with higher scores indicating greater cognitive
impairment (Cronbach’s a = 0.82; correlation with
MMSE -0.81) [32]. In addition, the evaluator used the
Erlangen Test of ADL (E-ADL test) [33] to measure the
ability of dementia patients to carry out basic ADLs
under standardized conditions (that is, pouring a drink,
cutting a piece of bread, opening a small cupboard,
washing one’sh a n d s ,a n dt y i n gab o w ) .T h es c o r i n g
range for the E-ADL test is 0 to 30, with higher scores
indicating less impairment (a =0 . 7 7 ) .T h eE - A D Lt e s t
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with the Nurses’ Observation Scale for Geriatric Patients
(NOSGER): -0.60) [33].
Other measures
Study coordinators recorded each patient’sa g e ,g e n d e r ,
educational attainment, family status, and nursing care
needs at baseline. Nursing staff rated depressive symp-
toms among the patients at baseline using the mood
subscale of NOSGER (NOSGER-mood; test-retest relia-
bility: 0.85; correlation with the Geriatric Depression
Scale: rS = 0.63). Nursing care needs were determined
based on the three-level scale used in Germany to estab-
lish eligibility for nursing care benefits. The scale ranges
from care level 1 (moderate needs) to care level 3 (very
high needs), and each potential nursing home resident
in Germany is evaluated by the so-called long-term care
funds (Pflegekassen), which are quasi-public entities that
administer the German system of statutory long-term
care insurance.
We also calculated the effect of any previous medical
d i a g n o s e so nt h em o r t a l i t yr a t eu s i n gt h eC h a r l s o n
comorbidity index [34]. Potential bias resulting from
non-pharmacological and pharmacological interventions
was accounted for by using a participation score (regu-
lar, non-MAKS activities offered by the nursing homes
during the time of intervention) and a medication score
(sedative/stimulating effect of all medication at baseline).
C h a n g e si np r e s c r i p t i o nd u r ing the intervention time
were also recorded but occurred only in 16% of all cases
and were therefore not taken into account (for further
information see Tables 1 and 2).
Patients
All patients included in the study were white. At base-
line, there were no statistically significant differences
between the control and intervention groups (Table 1).
Only 13 patients (13.5%) were taking anti-dementia
medication at baseline. The patients who were excluded
(n = 434; for reasons see Figure 1) were an average of
83.1 years old and 77% were women, making them simi-
lar to the study participants in terms of age and gender
(see Table 1). Of the 98 patients ultimately included in
the study, 35 fulfilled our dropout criteria during the
12-month intervention (death, being bedridden, care
level 3, moving away, less than 50% participation, 3
weeks or more in hospital, refusal of therapy or study
participation): 16 in the control group and 19 in the
intervention group. Distribution of dropouts was
between 2 and 4 in all months with the only exceptions
being months 7 and 10 without any dropouts and
month 12 with 7 dropouts. Additionally, two patients
had to be excluded because they had received an incor-
rect diagnosis (see Figure 1). There were no differences
between the nursing homes with respect to participants’
age, gender, family status, MMSE score, use of anti-
dementia medication, or Charlson index scores (see
Table 1). There were, however, significant differences
between the nursing homes in terms of patients’ educa-
tional attainment and baseline scores on the E-ADL test
and ADAS-Cog subscale. We adjusted for these differ-
ences in our regression analysis.
Statistical analysis
We planned the study and assessed its results in colla-
boration with the Institute for Medical Informatics, Bio-
metry, and Epidemiology at the University of Erlangen,
Germany. In accordance with the study protocol, we
tested the study hypothesis in a per protocol (PP) analy-
sis (that is, of patients who did not drop out). We also
performed a sensitivity analysis according to an inten-
tion to treat (ITT) approach, which included all patients
who had been randomly assigned to the two groups at
baseline and were still alive after 12 months. In general,
we attempted to record outcome variables for all
patients who were still alive after 12 months (n = 79). If,
however, more than 20% of the items on the ADAS-Cog
subscale or the E-ADL test were missing for any given
patient (for example, because of his or her refusal to
complete the test), we computed the score according to
the expectation maximum (EM) algorithm, with the
variables showing the greatest proportion of explained
variance in the missing variable. These were always the
pertinent baseline value and the group assignment. The
scores recorded for patients who died during the study
period were not imputed. Under these conditions, impu-
tation was necessary in 10% of cases in the ITT analysis
and in no case in the PP analysis.
We examined group differences between the nursing
homes using the Kruskal-Wallis test or the c
2 test. Dif-
ferences at baseline were examined either with the c
2
test or with the t test for independent samples (Table
1). First, we tested differences between baseline and
endpoint for each group separately using the t test for
dependent samples (ADAS-Cog) and the Wilcoxon
signed rank test for non-parametric data (E-ADL). We
reported adjusted mean differences in the outcome vari-
ables with 95% confidence intervals. Moreover, we cal-
culated effect sizes (Cohen’s d) using pooled standard
deviation [35]. We defined a treatment benefit as a sta-
bilization of, or an improvement in, the respective out-
come measure; this definition served as the basis for
calculating the number needed to treat for each mea-
sure. Subsequently, we conducted multiple linear regres-
sion analyses using the 12-month follow-up scores for
the ADAS-Cog subscale and the E-ADL test as depen-
dent variables. The independent variables were included
in the regression equation by the enter method.
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variables used should not exceed the square root of the
sample size (here: n = 61). In addition to the baseline
values for each outcome variable and the group variable
(MAKS versus control group), we thus included only
those variables that showed sufficient variance (at least
10% per group in a dichotomous variable) in the sample
or that were not in multicollinear relationship (r > .5) to
the baseline values of the outcome variables (Table 2).
This resulted in a regression model with eight indepen-
dent variables that fulfilled the Altman criterion. We
conducted our statistical analysis using PASW 18.0 with
the significance level set at P <0 . 0 5 .A l la n a l y s e sw e r e
two-sided.
As an exploratory analysis Cohen’s d for the matched
subgroup of patients with only mild or moderate AD
according to their initial MMSE Scores (mild (18 to 23),
moderate (10 to 17) and severe (< 10) AD) was
calculated.
As a sensitivity analysis in case of differences between
nursing homes we performed a mixed model regression
analysis with ‘nursing home’ as random effect, and
group as allocation, along with a number of adjustment
factors (gender, age, use of anti-dementia drugs, medica-
tion score, mood, participation in non-MAKS activities,
baseline value) as fixed effects.
Results
At baseline, there were no significant differences
between patients who ultimately dropped out of the
study (n = 35) and patients who completed the 12-
month protocol (n = 61) in terms of age (dropouts
mean: 85.5 years; completers mean: 84.9 years; P =
0.58), gender (dropouts 86% women; completers 82%
women; P = 0.64), MMSE score (dropouts mean: 13.8;
completers mean: 15.1: P = 0.27), or care level (drop-
outs/completers: none: 3%/13%; care level 1: 51%/49%;
care level 2: 45%/38%; P = 0.24).
At the 12-month follow-up, the scores for the out-
come measures in the intervention group remained
unchanged as tested using the t test for dependent sam-
ples in the case of the ADAS-Cog subscale (baseline
mean: 32.6 SD: 11.5; 12-month follow-up mean: 32.5 SD
15.3; P = 0.99) and using the Wilcoxon signed rank test
in the case of the E-ADL test (baseline: 26.6 SD 5.1; 12-
months: 26.3 SD 5.4; P = 0.71). In contrast, the control
group showed an increase in impairment for both mea-
sures (that is, an increase in the ADAS-Cog score (base-
line: 35.6 SD: 14.8; 12-months: 40.8 SD17.0; P =0 . 0 3 9 )
and a decrease in the E-ADL test score (baseline: 24.3
SD: 5.6; 12-months: 21.5 SD: 7.4; P = 0.002). The num-
ber needed to treat (NNT) was 4.0 for the ADAS-Cog
subscale and 5.5 for the E-ADL test. The adjusted mean
differences between the two groups in the primary PP
analysis (n = 61) were -7.7 points (95% CI -14.0 to -1.4;
P = 0.018) for the ADAS-Cog subscale and 3.6 points
(95% CI 0.7 to 6.4; P = 0.014) for the E-ADL test.
Multivariate regression analysis showed that participa-
tion in MAKS was a significant predictor of cognitive
function and the ability to carry out ADL after 12
months (Table 2). Both regression models were signifi-
cant at P < 0.001. In both regression equations, the
baseline scores for the two outcome measures were sig-
nificant predictors of the corresponding follow-up score.
Table 2 Multiple regression analysis with ADAS-Cog and E-ADL test as dependant variable (PP analysis, n = 61)
ADAS-Cog (12-month follow-up) E-ADL test (12-month follow-up)
Independent variable
a Unstandardized b (95% CI) tP value Unstandardized b (95% CI) tP value
Score
b at baseline 0.82 (0.59-1.05) 7.14 < 0.001 0.80 (0.54-1.06) 6.23 < 0.001
Group (control = 0 vs. MAKS = 1) -7.67 (-13.97–1.37) -2.44 0.018 3.57 (0.72-6.42) 2.52 0.015
Age 0.13 (-0.47-0.73) 0.43 0.67 0.08 (-0.19-0.35) 0.58 0.57
Gender 1.02 (-6.90-8.94) 0.26 0.80 0.91 (-2.64-4.46) 0.51 0.61
Medication score
c -0.38 (-2.14-1.39) -0.43 0.67 -0.02 (-0.81-0.77) -0.05 0.96
NOSGER, mood
d 0.80 (-0.23-1.82) 1.56 0.13 -0.14 (-0.59-0.31) -0.63 0.53
Participation score
e -0.07 (-0.14–0.01) -2.22 0.03 0.01 (-0.02-0.04) 0.82 0.42
Use of anti-dementia medication
f -5.96 (-16.42-4.51) -1.14 0.26 0.76 (-3.91-5.43) 0.33 0.74
P-values < 0.05 are in bold
Abbreviations: ADAS-Cog, Alzheimer’s Disease Assessment Scale, subscale cognition; E-ADL test, Erlangen Test of Activities of Daily Living; PP, per protocol;
NOSGER, Nurses’ Observation Scale of Geriatric Patients.
aExcluded due to a lack of variance: educational attainment (93% with no more than elementary school education), excluded due to multicollinearity (r ≥ 0.50
with ADAS-Cog at baseline and/or E-ADL test at baseline): care level (0.76 with ADAS-Cog; 0.56 with the E-ADL test), Charlson comorbidity index (0.52 with ADAS-
Cog); Mini Mental State Examination (0.71 with ADAS-Cog; 0.56 with the E-ADL test).
bADAS-Cog at baseline if ADAS-Cog 12-month follow-up is dependent
variable; E-ADL test at baseline if E-ADL test 12-month follow-up is dependent variable.
cSedating (< 0) or stimulating (> 0) effect or side effect of the prescribed medications.
dNOSGER-mood subscale, which consists of five depression items rated on
a scale of 1 (always) to 5 (never). The score ranges from 5 (no disturbance) to 25 (maximum possible degree of disturbance).
eSum score of all non-MAKS activities regularly offered by the nursing homes and in which patients participated on a voluntary basis. The scores were recorded
by nursing staff each week throughout the observation period. Examples of such activities are singing groups or physical exercises to reduce the risk of falling.
Each activity in which a patient participated was rated with one point.
fUse of acetylcholinesterase (AChE) inhibitors or memantine.
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which a patient took part was another significant predic-
tor of the ADAS-Cog score (P = 0.03) after 12 months,
with a higher number of activities being predictive of
less cognitive impairment. Age, gender, NOSGER-mood
score, the use of anti-dementia medication, and the
impact of medication on psychomotor activities (medi-
cation score) had no predictive power.
I nt h eP Pa n a l y s i s( n=6 1 ) ,t h ee f f e c ts i z eo fM A K S
therapy was moderate both for cognition (d = 0.45) and
for the ability to perform ADL (d = 0.50). In the ITT
analysis (n = 79), the effect sizes were d = 0.33 and d =
0.23, respectively. Looking at patients with mild to mod-
erate dementia (MMSE 10 to 23) separately, the effect
sizes increased to d = 0.67 for the ADAS-Cog subscale
and d = 0.69 for the E-ADL test in the PP analysis (n =
50) and to d = 0.50 for the ADAS-Cog subscale and to
d = 0.35 for the E-ADL test in the ITT analysis (n = 63).
Mixed model regression analysis yielded evidence of a
significant impact of group allocation on ADAS-Cog (P
= 0,008) and E-ADL test (P =0 , 0 0 8 ) ,a d j u s t e df o rt h e
effect of nursing home allocation and a number of other
adjustment factors.
A total of 67 serious adverse events occurred in the
sample (n = 96) over 12 months, including 43 falls
resulting in injury (MAKS: 19; control: 24), 7 other
types of serious injury (MAKS: 3; control: 4), and 17
deaths (MAKS: 9; control: 8).
Discussion
MAKS therapy had a significant effect on cognitive func-
tion in dementia patients and on their ability to carry out
ADL in five participating nursing homes after 12 months
compared to a control group that received usual care.
The MAKS therapy was found to be an easily manageable
form of therapy which was well-accepted by the patients.
This is reflected in the very low number of missing days.
Treatment with cholinesterase inhibitors or memantine,
which was neither an inclusion nor an exclusion criterion
in our study, had been prescribed to only 13 patients
( 1 3 . 5 % ;s e eT a b l e1 )a n dp e r h a p sh a d ,t h e r e f o r e ,n op r e -
dictive power. The effect sizes of MAKS therapy were in
the same range as those that have been reported for cho-
linesterase inhibitors with respect to cognition and about
twice as high as those reported for cholinesterase inhibi-
tors with respect to ADL [4]. One fourth of the patients
in the intervention group dropped out during the study
period or were lost to follow up, leading to lower effect
sizes in our ITT analysis. In the intervention group, the
effect sizes in patients with mild to moderate dementia
were substantially higher than in patients with severe
dementia. As a consequence, MAKS therapy, until
further investigation with a larger sample size, should not
be used in the latter patient group.
In a systematic search of the literature for comparable
multicomponent, non-pharmacological RCTs in which
the primary target group consisted of dementia patients
and not of their caregiving family members, we were
unable to identify any methodologically rigorous studies
that had been conducted in a nursing home setting. Our
search did reveal, however, that various combinations of
non-pharmacological interventions have been conducted
in community-dwelling dementia patients to date. Onor
et al. [37], for example, investigated the efficacy of com-
bined cognitive and occupational therapy but were
unable, perhaps due to the small size of their sample (n
= 32), to find any significant effects for the outcome
measures cognition, ADL, or instrumental ADL. In
another study, a significant effect on the ADAS-Cog
subscale was demonstrated for an intensive intervention
with 103 sessions that took place over a 12-month per-
iod and combined cognitive and motor elements in a
sample similar in size (n = 84) to ours [19]. The evalua-
tors were blinded to treatment allocation. Moreover, all
patients had been receiving treatment with an acetylcho-
linesterase inhibitor and continued to do so during the
study period. The authors, however, did not report
effect sizes and only cursorily described the effects of
the intervention at 12 months. A significant effect on
patients’ ability to carry out ADL could not be demon-
strated. Gitlin et al. [38] investigated the efficacy of a
multicomponent non-pharmacological intervention
regarding functional abilities of community-dwelling
dementia patients and several other outcomes. The
intervention group (n = 102 dyads of dementia patient
and caregiver) received up to 10 sessions with occupa-
tional therapists aimed at reducing environmental stres-
sors and enhancing caregiver skills. Therapists identified
strengths and deficits of the patients and trained care-
givers in modifying home environment and communica-
tion. Additionally, health related information was
assessed and recommendations were provided to the
caregiver to share with the patients’ physicians. The
control dyads (n = 107) received up to three telephone
calls from research staff and informational material was
provided. After four months, significant improvements
in functional dependence could be found for the inter-
vention group compared to the control group. Cohen’s
d was 0.21, mainly due to an improvement in IADL-
abilities. The effect could no longer be found after nine
months. Outcome measures were caregiver ratings,
obtained by interviewers blinded to participant group. In
summary, our literature search revealed that the multi-
component interventions conducted among community-
dwelling patients to date have shown only moderate
effects. While this may be attributable to the type or
intensity of therapy, it may also be related to the lack of
consistently applied blinded performance tests. Because
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the identified studies had sustained effects, we defined
the PP analysis as our primary evaluation strategy.
The present study has several important limitations.
The first of these is the size of its sample, which con-
sisted of 61 dementia patients in the PP analysis. This is
in the middle range compared to the study samples in
other non-pharmacological, multicomponent RCTs in
dementia patients, which have had between 32 [37] and
209 [38] participants, albeit in a community-dwelling
rather than a nursing-home setting. Future studies of
M A K St h e r a p ys h o u l di n c l u d eal a r g e rs a m p l eo f
patients. The second limitation of our study is its lack
of a control group receiving placebo treatment. In light
of the many drawbacks of non-pharmacological placebo
treatments, however, we feel that the use in our study of
a control group receiving usual care was appropriate,
especially considering that we placed no restrictions on
patients in either group with regard to their continua-
tion or initiation of any pharmacological or non-phar-
macological treatment during the study period. All
control group participants were allowed, for example, to
continue to take part in the regular, non-MAKS activ-
ities offered by their nursing home, which they did on
the average twice a week. As participation in these activ-
ities was voluntary, the significant effect on cognition
after 12 months might either be due to helpfulness of
these activities but also due to a convenience sample.
The treatment effects of MAKS therapy are undoubt-
edly attributable not only to specific but also to non-
specific factors, such as the attention paid to patients by
the therapists. To date, however, no studies have been
able to demonstrate that paying more attention to
patients, as for example is practiced in validation ther-
apy, can produce a significant cognitive improvement in
and of itself [39]. It therefore seems unlikely that the
effects of MAKS therapy are attributable only to the
greater intensity and duration of the attention paid to
patients in the intervention group.
Our study also has a number of strengths compared
to previous investigations. With only a few exceptions
(for example, our decision not to include bed-ridden
patients), our choice of inclusion and exclusion criteria
closely reflects the clinical reality of dementia patients
in nursing homes: Unlike many other studies of non-
pharmacological interventions in this patient group, we
did not exclude patients who showed poor cognitive
function as measured by the MMSE or possible neurop-
sychiatric symptoms, such as challenging behavior.
Another strength of our study was the rigorous standar-
dization of MAKS therapy through the use of a hand-
book, enabling a high degree of agreement across the
participating nursing homes. In addition to repeated
trainings of the therapists, additional quality assurance
measures were performed with all of the study and nur-
sing home staff who participated in the investigation.
Finally, in terms of methodology, another strength of
our study was its use of external evaluators who were
blinded to treatment allocation to assess both outcome
variables. Moreover, additional factors that might influ-
ence treatment, such as medication or participation in
additional, non-MAKS activities, were included in the
multivariate analysis, and any serious adverse events
were recorded.
Patients with dementia always experience limitations
with respect to an age-appropriate ‘participation in life’
due to the symptoms of their disease and especially as
nursing home residents. These limitations particularly
affect social interaction, communication, cognition and
everyday practical stimulation. The MAKS therapy aims
at restoring this participation appropriate to the
resources still available to the patient, and thus is char-
acterized by multimodality, regularity and various
degrees of difficulty.
Due to the standardization of the MAKS therapy and
publication of a handbook [40], the therapy is easy to
implement and requires little preparation time from the
therapists. In the present study, the MAKS therapy was
carried out in an intensive form. Performance as group
therapy reduces the per-person costs of intervention.
With two therapists for ten patients, the therapy costs
are below €10/day and person and are thus still in the
range of costs of therapy with acetylcholinesterase inhi-
bitors. Moderately higher costs appear justified when
the non-drug therapy shows no adverse effects and is at
least as effective as therapy with acetylcholinesterase
inhibitors. In the future, health economic studies to
compare these costs to the possible savings which could
result from stabilization of the patient’s capabilities, and
thus on the costs of care would be desirable.
The German health system includes, for example, so-
called supplementary care services for the care of
patients with dementia. The aim should be to use these
resources in such a way that the dementia patient
receives the maximum benefit. Depending on the health
system, there are various types of resources which sup-
port dementia patients or aid in integrating them in
everyday living. It appears promising to make appropri-
ate use of the possibilities of non-drug therapy in the
care of dementia patients.
Conclusions
MAKS therapy preserved the cognitive function and
ability to carry out ADL and thus, the independence, of
dementia patients with mild to moderate dementia in
nursing homes for at least 12 months without adverse
effects. Future studies of MAKS therapy should include
a larger sample of patients, more measurement points to
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up period to determine if the stabilization seen at 12
months can be maintained for longer periods, and if
there is any durable effect after treatment is stopped. It
will also be important to determine whether MAKS
therapy leads to improvements in standardized measures
of quality of life.
Finally, future research should focus on any cumula-
tive effects with anti-dementia drugs, and on the ques-
tion of whether some form of MAKS therapy might be
beneficial to dementia patients in an outpatient setting.
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